New drug
VSY Biotechnology GmbH has announced that a new drug named TR-C 19 has been developed to treat COVID-19 by the company’s research centre. Studies have shown that TR-C 19 can neutralise the virus isolated under laboratory conditions, according to VSY. The drug is now at the authority approval stage for usage on voluntary COVID-19 patients and clinical trial.
“[This] is one of the most meaningful projects that we have been developing,” said Dr Ercan Varlibas, Chairman of the Board of Directors of VSY Biotechnology GmbH.
https://www.vsybiotechnology.com/
Latest Articles
Simulators Benefit Surgeons and Patients
Helping young surgeons build confidence and expertise.
How Many Surgeries Equal Surgical Proficiency?
Internet, labs, simulators, and assisting surgery all contribute.
Improving Clinical Management for nAMD and DME
Global survey data identify barriers and opportunities.
Are Postoperative Topical Antibiotic Drops Still Needed?
Cataract surgeons debate the benefits of intracameral cefuroxime prophylaxis.
Emerging Technology for Detecting Subclinical Keratoconus
Brillouin microscopy shows promise in clinical studies.
Knowing Iris Repair: Modified Trifold Technique
Part eight of our series covers the modified trifold technique for large iris defects.
It’s All About Biomechanics!
Increasing the pool of patients eligible for refractive surgery.
Uncovering More Safe and Quick Options
Different strategies, such as PresbyLASIK, can offer presbyopes good outcomes.
Topography-Guided PRK for Keratoconus
Improving visual acuity in patients with keratoconus.
Defining AMD Treatment Protocol
Treatments trending to fewer injections for better results.